Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas

Authors
Faramand, AndrewKano, HideyukiNiranjan, AjayPark, Kyung-JaeFlickinger, John C.Lunsford, L. Dade
Issue Date
7월-2019
Publisher
ELSEVIER SCIENCE INC
Keywords
Cranial nerve; Meningioma; Radiation; Radiosurgery; Skull base
Citation
WORLD NEUROSURGERY, v.127, pp.E221 - E229
Indexed
SCIE
SCOPUS
Journal Title
WORLD NEUROSURGERY
Volume
127
Start Page
E221
End Page
E229
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/64234
DOI
10.1016/j.wneu.2019.03.052
ISSN
1878-8750
Abstract
OBJECTIVE: We evaluated the tumor control and cranial nerve (CN) outcomes after adjuvant stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. METHODS: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had >= 1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22-81). SRS was performed for residual tumor in 104 patients (69%) and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm(3) (range, 0.3-42), and the median margin dose was 13 Gy (range, 10-20). RESULTS: Tumor control was achieved in 135 patients (90%) at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%) reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years. CONCLUSIONS: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE